Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Net revenue:
Total net revenues	$ 3,545	$ 2,850	$ 7,242	$ 5,009
Cost of goods sold	1,466	1,455	3,052	2,561
Gross margin	2,079	1,395	4,190	2,448
Operating expenses:
Selling, general and administrative	2,239	1,885	4,363	4,062
Research and development	221	273	460	645
Depreciation and amortization	54	51	108	102
Total operating expenses	2,514	2,209	4,931	4,809
Operating loss from continuing operations	(435)	(814)	(741)	(2,361)
Other (expense) income:
Interest expense		(6)	(1)	(13)
Interest income	13	1	25	3
Other income (expense), net	(11)	72	(22)	63
Total other expense:	2	67	2	53
Loss from continuing operations	(433)	(747)	(739)	(2,308)
Net loss from discontinued operations		(390)		(796)
Net loss	(433)	(1,137)	(739)	(3,104)
Less: Undeclared deemed dividend attributable to noncontrolling interest		(66)		(129)
Net loss attributable to Nephros, Inc. shareholders	$ (433)	$ (1,203)	$ (739)	$ (3,233)
Net loss per common share, basic from continuing operations	$ (0.04)	$ (0.07)	$ (0.07)	$ (0.22)
Net loss per common share, diluted from continuing operations	(0.04)	(0.07)	(0.07)	(0.22)
Net loss per common share, basic from discontinued operations		(0.04)		(0.08)
Net loss per common share, diluted from discontinued operations		(0.04)		(0.08)
Net loss per common share, basic	(0.04)	(0.11)	(0.07)	(0.30)
Net loss per common share, diluted	(0.04)	(0.11)	(0.07)	(0.30)
Net loss per common share, basic, attributable to continuing noncontrolling interest		(0.01)		(0.01)
Net loss per common share, diluted, attributable to continuing noncontrolling interest		(0.01)		(0.01)
Net loss per common share, basic, attributable to Nephros, Inc, shareholders	(0.04)	(0.12)	(0.07)	(0.31)
Net loss per common share, diluted, attributable to Nephros, Inc, shareholders	$ (0.04)	$ (0.12)	$ (0.07)	$ (0.31)
Weighted average common shares outstanding, basic	10,297,429	10,299,148	10,297,429	10,265,267
Weighted average common shares outstanding, diluted	10,297,429	10,299,148	10,297,429	10,265,267
Comprehensive loss:
Net loss	$ (433)	$ (1,137)	$ (739)	$ (3,104)
Other comprehensive loss, foreign currency translation adjustments, net of tax				(3)
Comprehensive loss	(433)	(1,137)	(739)	(3,107)
Comprehensive loss attributable to noncontrolling interest		(66)		(129)
Comprehensive loss attributable to Nephros, Inc. shareholders	(433)	(1,203)	(739)	(3,236)
Product [Member]
Net revenue:
Total net revenues	3,537	2,837	7,199	4,988
Royalty and Other Revenues [Member]
Net revenue:
Total net revenues	$ 8	$ 13	$ 43	$ 21